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Summary.-The seraof73patients withnasopharyngeal carcinoma(NPC),28patients
with other carcinomas (OC) and 89 healthy subjects (HS) were tested for IgG and IgA
antibodies to Epstein-Barr virus (EBV) viral capsid antigen (VCA). The majority
of the NPC sera had IgG titres of 160 or above, whereas the majority of the other
sera had titres below 160. For IgA reactivity to EBV-VCA,68 of73 (93*2%) NPC sera
had titres of > 10. In contrast, only 6 of28 (21-4%) OC sera and none of the HS sera
had such titres. The mean serum concentrations of IgG, IgA, IgM and C3' were also
determined in 55 NPC and 20 OC patients and 18 HS. They were all significantly
higher in the NPC sera than in the HS. Although the concentrations of IgG and C3'
were not significantly different in the two carcinoma groups, the concentrations of
IgA and IgM were significantly higher in the NPC group than in OC. These findings
appear to reflect the intensity of EBV-specific antigenic stimulation in NPC, and the
EBV-specific serum IgA reactivity may be a useful aid to the diagnosis of NPC,
especially in cases with an occult primary tumour. It may be also of value as a
screening test in people at high risk.
AN ASSOCIATION of the Epstein-Barr
virus (EBV) with nasopharyngeal carci-
noma (NPC) is now firmly established.
Old et al. (1966) first demonstrated the
presence of precipitating antibodies to
EBV-related antigens in sera from patients
with the cancer. This discovery was fol-
lowed by the demonstration that NPC
patients in widely separated parts of the
world had higher geometric mean titres
(GMT) of antibodies to EB viral capsid
antigen (VCA) than those of control
groups, made up of patients with other
head and neck cancers and normal subjects
(de Schryver et al., 1969. 1974; Henle et
al., 1970; Lin et at., 1971; Henderson
et al., 1974; Desgranges et al., 1975). The
GMT of antibodies to VCA increases with
advancing clinical stage of the disease
(Ho, 1970; Henle et al., 1970, 1973;
de-The et al., 1975). de-The et al. (1975)
demonstrated that VCA titre correlated
with titres of antibodies to 3 other EBV-
specific antigens: early antigen (EA),
nuclear antigen (EBNA) and soluble
antigen (CF/S). Henle et al. (1973)
showed in NPC, that antibodies to the
diffuse (D) component of the EBV-
induced EA was not usually demonstrable
in Stage I of the disease, but from Stage
II onward there was an increasingly
higher titre. Thus, it would seem that
the various EBV antibodies are related to
the total tumour burden.
Wara et at. (1975) reported elevated
levels of IgA in NPC patients. Henle and
Henle (1976), stimulated by this report,
investigated the levels of serum IgA
antibodies to VCA and to diffuse (D) or
restricted (R) components of the EBV-
induced EA complex in NPC patients and
control subjects. They found NPC sera
to be outstanding in that, prior to specific
therapy, 93% of the sera revealed IgAH. C. HO, MUN H. NG, H. C. KWAN AND J. C. W. CHAU
antibodies to VCA and 70% to D, often
at high titres, and that Stages III and IV
patients' sera had higher titres than that
from patients at Stages I and II. This may
be interpreted as related to total tumour
burden. Patients examined 2-6 years
after therapy, had only low levels of
EBV-specific IgA or none at all, except
in those with recurrent disease. Less
than 5% of 73 patients with other carci-
nomas and of 76 healthy donors revealed
the presence of such antibodies. Like
the Henles, we were prompted to study
the IgA antibodies to VCA in sera from
Chinese NPC patients and control subjects
in Hong Kong. In addition, we also
studied the serum IgA, IgG, IgM and
complement C3' concentration of some of
these patients and healthy subjects.
MATERIAL AND METHODS
Sera were obtained before specific therapy
from 73 NPC patients (12 Stage 1, 3 Stage II,
50 Stage III, 6 Stage IV and 2 Stage V
disease, according to Ho's stage classification
(Ho, 1970)) and 28 patients with other
carcinomas (OC) (14 bronchus, 9 head and
neck, 2 cervix, 2 urinary bladder and 1
rectum) and from a group of89 healthy adult
subjects (HS) consisting of 27 volunteers, 44
blood donors and 18 patients due fordischarge
from traumatic wards of Queen Elizabeth
Hospital.
Sera were routinely stored in small
aliquots at - 70°C until used. IgG anti-
VCA titres were determined according to the
methodofHenleandHenle (1966)andreacting
cell smears prepared from Jijoye cell line with
diluted serum aliquots and counter-stained
with fluorescein-conjugated (FITC) goat anti-
human IgG (Dako, Copenhagen). The
results were expressed as the reciprocal of
the maximum serum dilution giving positive
fluorescent staining of the cell smears. To
detect IgA anti-VCA, sera were diluted 1: 10
with PBS, and similarly reacted with the
Jijoye cell smears, which were then counter-
stained with FITC goat anti-human IgA
(Dako, Copenhagen).
Serum immunoglobulin and complement
C3' concentrations were estimated in some of
the sera by the radial immuno-diffusion
method (Mancini et al., 1964) using com-
mercial immunoplates (Hyland, U.S.A.). It
should be noted that this method may not be
wholly quantitative for IgA, which exists in
different polymeric forms which interfere with
the test.
RESULTS
The results of the tests for IgG and
IgA antibodies to EBV-VCA obtained
with the sera from the various groups, are
shown in the Fig., and compared in
Table I. Of the 73 NPC patients, 68
(93.2%) showed IgA antibodies to VCA
at titres of >10. In contrast, the fre-
quency was only 5 of 28 (17.9%) in the
OC group and 0% in the HS. The differ-
ence in frequency between the NPC and
the OC or HS groups is significant, but
there isalso asignificantdifferencebetween
the OC and HS groups. Of the 5 NPC
cases with IgA antibodies to VCA at
titres of >10, 4 were among the 12 Stage
I and only 1 among the 50 Stage III
cases. The correlation between EBV-
specific IgAand IgG antibodies is evident
from the Fig. (r = 0.81). If an IgG anti-
VCA titre of 160 is chosen arbitrarily as
the lower limit of the high range, the
majority of the NPC sera tested fell
TABLE I.-IgG and IgA Antibodies to EBV-VCA in Sera of NPC and Control Groups
Sera
A
Source Number
NPC 73
IgG anti-VCA
I A
GMT (95% confidence
interval)
750 (914-616)
OC 28 149 (190-117)
HS 89 58 (70-48)
* Calculated by Student's t test.
Group
compared
OC
HS
HS
*p
<0-001
<0-001
<0-001
IgA anti-VCA
Number of sera with Group
titre > 10 (%) compared *P
68 (93.2) OC <0*001
HS <0*001
5 (17-9) HS <0-001
0 (0)
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Fi.- Correlation between IgA and IgG antibody titres to VCA in NPC patients and controls.
above this limit, and the majority of the
others below it. Discordance in the cor-
relation was observed in only 6 of 190 sera
tested. Two of the 6 were from the OC
group and 4 from HS. They all had IgA
anti-VCA titre of <10 and high IgG
anti-VCA titres. None had the reverse
combination.
The mean serum concentrations of
IgG, IgA, IgM and C3' for the various
groups are shown in Table II. They were
significantly higher in the NPC group
than in the HS. Although the mean
concentrations of IgG and C3' were not
significantly different in the two carcinoma
groups, the concentrations of IgA and
IgM were significantly higher in the NPC
group than in the OC (Table II).
DISCUSSION
For some time it was thought that,
since EBV is lymphotropic, the serological
manifestations might not have anything
to do with the tumour cells, which are of
epithelial origin. Now, EBV-DNA and
EBNA have been demonstrated in the
anaplastic and poorly differentiated squa-
mous carcinoma cells of fresh NPC
biopsies (Wolf, zur Hausen and Becker,
1973; Wolf et al., 1975; Klein et al.,
1974; Huang et al., 1974). The carcinoma
cells, or at least some of them, have been
shown by Glaser et al. (1976) to possess
the receptor for EBV, and their
resident EBV genome could be induced by
iododeoxyuridine (IUdR) to express EA.
Furthermore Trumper, Epstein and Gio-
vanella (1976) obtained a pure culture of
NPC cells by passage of NPC tissue
through athymic nude mice, and demon-
strated that these cells could be induced
by treatment with bromodeoxyuridine
(BUdR) to express EA, and produce
immature and mature herpesvirus par-
ticles which were antigenically related to
EBV. The presence of EBV genomes in
the tumour cells of NPC is, therefore,
beyond doubt. The question is whether
they have anything to do with the genesis
of NPC.
Henle and Henle (1976) raised the
possibility that the IgA antibodies to
EBV might originate from the secretory
immune system rather than the systemic.
Since, as mentioned earlier, the resident
EBV genomes in NPC cells could be
induced by IUdR to express EA (Glaser,
1976) and by BUdR to express EBV
20
10
>
l
1ii
U
I
z
-.
w
IL
w
m
z
uI
0
0a
657
_
_
n)
2
lH. C. HO, MUN H. NG, H. C. KWAN AND J. C. W. CHAU
* woo0
C)
CO C)iCO
+- - v
8 ++
0 e
_ _
aq "Id
_
C 00
* 00 w
v ri
C)
10 CICO to Gi m
-H-H
00 I" m
m 0
4C
CO OO
0 bo
658
CC
o
0
o re
-H
0
0
0t
.
0~
o )
C)
I.f
H
000
* 000 VVV
d
0 O
C)
O 0
t- Co
0q -410
+ +HH
CO 00
10 coCai
_ N~
O O
100
-i- v 2
6 g O 4L
C) 03
CS CO o
00 _ino Z
C) 10 O 1li
c
4 ---)
I
co
Q
bD
.-q
I I -1 - I.,IgA AND IgG IN NASOPHARYNGEAL CA 659
particles (Trumper et al., 1976), it is
conceivable that the almost exclusively
high frequency and titres of EBV-specific
IgA in NPC might be derived locally in
response to the tumour. The existence
of such a state of antigenic stimulation
might be expected to have resulted in a
random assortment of serum IgG and
IgA anti-VCA. The finding to the con-
trary therefore appears to indicate that
both types ofVCA-specific serum immuno-
globulins might be produced in concert
with one another. The fact that serum
IgA anti-VCA was detected largely in
NPC patients might then reflect, at least
in part, the intensity of antigenic stimu-
lation. Consistent with this interpreta-
tion, an overall increase in immuno-
globulins and C3' concentrations was also
observed in sera of NPC patients. The
present findings, however, do not exclude
the occurrence of local stimulation of
immune responses by EBV antigens in
NPC patients, and this question is being
currently assessed directly by measuring
EBV-specific antibodies and immuno-
globulin levels in the naso-oropharyngeal
secretions. Whatever the cause of this
serum immunoglobulin manifestation in
NPC, the test for EBV-specific serum
IgA reactivity appears to be a useful aid
to the diagnosis of NPC, especially in
those cases with carcinomatous cervical
nodal metastases or cranial nerve involve-
ment, but an occult primary tumour. It
may also be a useful screening test for the
cancer in people of high risk, such as
southern Chinese and members of families
with multiple cases, who have been shown
by Ho (1971, 1972a, b) to have an in-
creased risk.
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